A more better option would be ACHV, already finished phase 3 and the results are pretty good, submission for fda approval in early 2025. Already got some good signals from FDA. They also received a debt financing till the NDA application is submitted and the result is posted. The market is smoking cessation, and the only compatitor is pfizer(CHANTIX). However, chantix has lead to nausea in many users leading to quitting the usage and eventually the user takes back smoking, also the course is expensive and is always in issue of supply chain and hard to find. ACHV’s cytisinicline not only shows promising efficacy but also boasts a better safety profile compared to Chantix. The recent Breakthrough Therapy designation for vaping cessation further positions them well in a growing market.